Through a new partnership with Kaleo, manufacturer of naloxone auto-injectors, Brightside Clinic in Northbrook, Ill., is expanding its focus from medication-assisted treatment for opioid addiction to including medication-assisted prevention, as well.
Brightside, which has treated nearly 700 patients since opening its doors two years ago, has set a goal of prescribing 1,000 Evzio (naloxone) auto-injectors through the program, which allows recipients with commercial insurance to obtain the devices with little to no out-of-pocket cost. Purchasing an auto-injector otherwise can potentially cost as much as $4,500—a widely publicized list price increase by Kaleo that drew the attention of the U.S. Senate in February.
“We jumped on it quickly because we understood the cost was pretty prohibitive for some people to get this,” says Phil Atteberry, Brightside co-founder and CEO. “We wanted to jump on the program as soon as possible to start getting [the injectors] out there.”
Through the Kaleo initiative, private insurance can cover part of the cost of the devices, with the manufacturer absorbing most of the remaining cost. The products also can be delivered to recipients’ homes. Individuals with Medicare or Medicaid are eligible to instead receive Narcan intranasal naloxone spray, manufactured by Adapt Pharma, at a cost of $3.
Those interested in obtaining an Evzio auto-injector do not have to be a patient at Brightside, nor do they have to be in a recovery program. Atteberry says his clinic was approached by Kaleo, but he encourages other providers to reach out to the manufacturer to get involved.
“We would ask other prescribers to take the same mission: to be able to contact Kaleo to also sign up for this kind of program … and try to find a way to get this medication into the community,” Atteberry says. “It’s so important to have this ability to have a second chance at getting into recovery and overcoming this disease.”
Editor's note: This story was updated on May 5, 2017, to clarify that Evzio injectors are available to individuals with private insurance, while Narcan intranasal spray is available through Medicare and Medicaid at a cost of $3.